These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23544761)

  • 21. Cost-effectiveness of a lifestyle intervention in high-risk individuals for diabetes in a low- and middle-income setting: Trial-based analysis of the Kerala Diabetes Prevention Program.
    Sathish T; Oldenburg B; Thankappan KR; Absetz P; Shaw JE; Tapp RJ; Zimmet PZ; Balachandran S; Shetty SS; Aziz Z; Mahal A
    BMC Med; 2020 Sep; 18(1):251. PubMed ID: 32883279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
    Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial.
    Diabetes Prevention Program Research Group
    Diabetes Care; 2015 Jan; 38(1):51-8. PubMed ID: 25336746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An update on the Diabetes Prevention Program.
    Ratner RE;
    Endocr Pract; 2006; 12 Suppl 1(Suppl 1):20-4. PubMed ID: 16627375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
    Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
    Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.
    Perreault L; Pan Q; Mather KJ; Watson KE; Hamman RF; Kahn SE;
    Lancet; 2012 Jun; 379(9833):2243-51. PubMed ID: 22683134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom.
    Palmer AJ; Roze S; Valentine WJ; Spinas GA; Shaw JE; Zimmet PZ
    Clin Ther; 2004 Feb; 26(2):304-21. PubMed ID: 15038953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was.
    Rittenhouse BE; Alolayan S; Eguale T; Segal AR; Doucette J
    Diabetes Obes Metab; 2024 Nov; 26(11):5097-5106. PubMed ID: 39143657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study.
    Goldberg RB; Orchard TJ; Crandall JP; Boyko EJ; Budoff M; Dabelea D; Gadde KM; Knowler WC; Lee CG; Nathan DM; Watson K; Temprosa M;
    Circulation; 2022 May; 145(22):1632-1641. PubMed ID: 35603600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP).
    Ramachandran A; Snehalatha C; Yamuna A; Mary S; Ping Z
    Diabetes Care; 2007 Oct; 30(10):2548-52. PubMed ID: 17670917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
    Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
    BMC Health Serv Res; 2015 Nov; 15():496. PubMed ID: 26541516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT.
    Griffin SJ; Bethel MA; Holman RR; Khunti K; Wareham N; Brierley G; Davies M; Dymond A; Eichenberger R; Evans P; Gray A; Greaves C; Harrington K; Hitman G; Irving G; Lessels S; Millward A; Petrie JR; Rutter M; Sampson M; Sattar N; Sharp S
    Health Technol Assess; 2018 Apr; 22(18):1-64. PubMed ID: 29652246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China.
    Xie X; Vondeling H
    Value Health; 2008 Mar; 11 Suppl 1():S23-32. PubMed ID: 18387063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
    Cai X; Shi L; Yang W; Gu S; Chen Y; Nie L; Ji L
    J Med Econ; 2019 Apr; 22(4):336-343. PubMed ID: 30663458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
    Chakravarty A; Rastogi M; Dhankhar P; Bell KF
    J Med Econ; 2018 May; 21(5):497-509. PubMed ID: 29376760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term effects of lifestyle and metformin interventions in DPP on bone density.
    Schwartz AV; Pan Q; Aroda VR; Crandall JP; Kriska A; Piromalli C; Wallia A; Temprosa M; Florez H;
    Osteoporos Int; 2021 Nov; 32(11):2279-2287. PubMed ID: 34086101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic evaluation of type 2 diabetes prevention programmes: Markov model of low- and high-intensity lifestyle programmes and metformin in participants with different categories of intermediate hyperglycaemia.
    Roberts S; Craig D; Adler A; McPherson K; Greenhalgh T
    BMC Med; 2018 Jan; 16(1):16. PubMed ID: 29378576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study.
    ; Orchard TJ; Temprosa M; Barrett-Connor E; Fowler SE; Goldberg RB; Mather KJ; Marcovina SM; Montez M; Ratner RE; Saudek CD; Sherif H; Watson KE
    Diabet Med; 2013 Jan; 30(1):46-55. PubMed ID: 22812594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design.
    Sun X; Guo L; Shang H; Ren M; Wang Y; Huo D; Lei X; Wang H; Zhai J
    Trials; 2015 Nov; 16():496. PubMed ID: 26530718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing the potential return on investment of the proposed UK NHS diabetes prevention programme in different population subgroups: an economic evaluation.
    Thomas C; Sadler S; Breeze P; Squires H; Gillett M; Brennan A
    BMJ Open; 2017 Aug; 7(8):e014953. PubMed ID: 28827235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.